Sarsia Seed Management

Heimdall Power AS is a technology company based in Bergen, Norway, that specializes in smart grid solutions for the energy sector. Established in 2015, the company develops a sensor platform called Neuron, which enhances situational awareness along transmission lines and distribution feeders. This platform includes features such as line monitoring, real-time feeder visualization, fault detection and analysis, dynamic line rating, and quality assurance. By utilizing advanced technologies like artificial intelligence and machine learning, Heimdall Power provides grid owners with critical real-time data on parameters such as temperature, load, and line sag. This data aids in optimizing and digitizing power grid infrastructure, ultimately improving efficiency, reliability, and sustainability while facilitating the transition to renewable energy sources.

Heimdall Power AS is a technology company based in Bergen, Norway, that specializes in smart grid solutions for the energy sector. Established in 2015, the company develops a sensor platform called Neuron, which enhances situational awareness along transmission lines and distribution feeders. This platform includes features such as line monitoring, real-time feeder visualization, fault detection and analysis, dynamic line rating, and quality assurance. By utilizing advanced technologies like artificial intelligence and machine learning, Heimdall Power provides grid owners with critical real-time data on parameters such as temperature, load, and line sag. This data aids in optimizing and digitizing power grid infrastructure, ultimately improving efficiency, reliability, and sustainability while facilitating the transition to renewable energy sources.

Sonoclear AS, founded in 2016 and located in Trondheim, Norway, specializes in manufacturing an acoustic coupling fluid designed for brain tumor surgery. The company's flagship product, SonoClear®, enhances ultrasound imaging by eliminating image artifacts that can occur in resection cavities during surgical procedures. This innovative technology supports medical professionals by improving the clarity of imaging, thereby aiding in clinical decision-making during brain surgeries.

BerGenBio is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for aggressive cancers. Its leading drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical evaluation in a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). Additionally, bemcentinib is in preclinical development for applications related to severe respiratory infections. The company's commitment lies in addressing significant unmet medical needs in oncology and beyond.

APIM Therapeutics AS is a biotechnology company based in Trondheim, Norway, specializing in the development of combinatorial therapies for cancer treatment. Founded in 2009, the company focuses on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA), a crucial protein involved in DNA repair and cellular responses to stress. APIM Therapeutics is advancing its lead compound, ATX-101, which has demonstrated proof-of-concept in various preclinical in vitro and in vivo cancer models. The company's innovative approach aims to disrupt the interactions between PCNA and its binding partners, offering potential strategies to eliminate cancer-specific tumor cells.

BerGenBio is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for aggressive cancers. Its leading drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical evaluation in a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). Additionally, bemcentinib is in preclinical development for applications related to severe respiratory infections. The company's commitment lies in addressing significant unmet medical needs in oncology and beyond.

APIM Therapeutics AS is a biotechnology company based in Trondheim, Norway, specializing in the development of combinatorial therapies for cancer treatment. Founded in 2009, the company focuses on proprietary peptide drugs that target proliferating cell nuclear antigen (PCNA), a crucial protein involved in DNA repair and cellular responses to stress. APIM Therapeutics is advancing its lead compound, ATX-101, which has demonstrated proof-of-concept in various preclinical in vitro and in vivo cancer models. The company's innovative approach aims to disrupt the interactions between PCNA and its binding partners, offering potential strategies to eliminate cancer-specific tumor cells.

BerGenBio is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for aggressive cancers. Its leading drug candidate, bemcentinib, targets the receptor tyrosine kinase AXL and is currently undergoing clinical evaluation in a Phase 1b/2a study for first-line treatment of STK 11 mutated non-small cell lung cancer (NSCLC). Additionally, bemcentinib is in preclinical development for applications related to severe respiratory infections. The company's commitment lies in addressing significant unmet medical needs in oncology and beyond.

Isentio is a cloud-based software company that specializes in enhancing the bacterial identification process through advanced DNA analysis methods. Their primary product, RipSeq, is an online application designed to facilitate rapid identification of bacteria in clinical samples, particularly those containing mixed bacterial populations. By leveraging sophisticated algorithms and a comprehensive microbial database, Isentio's solutions significantly reduce the turnaround time from sample collection to reporting, thereby improving infection management and patient outcomes. Founded in 2014 and based in Santa Cruz, California, Isentio aims to streamline the diagnostic process for complex infections, making it a valuable tool for healthcare providers.

Avexxin's therapeutic approach is built on more than a decade of research into the biological mechanisms involved in inflammatory diseases at the Norwegian University of Science and Technology. Avexxin's goal is to create a therapeutic company based on the discovery and development of novel therapeutics that address the fundamental mechanisms involved in inflammatory diseases.

WindSim AS is a Norwegian company based in Tonsberg that specializes in software for simulating wind resources in complex terrains. Its primary product, WindSim, is designed to optimize energy production from wind turbines across various regions, including Europe, Asia, Australia, and North America. The software employs advanced computational fluid dynamics and automated deep neural learning to enhance the efficiency of energy projects by accurately forecasting energy production and efficacy. In addition to its software offerings, WindSim AS provides consulting and training services to assist users in maximizing the benefits of its technology. The company distributes its products through partners in multiple countries, including China, France, Germany, Italy, Spain, and Taiwan. WindSim AS was previously known as VECTOR AS before rebranding in December 2005.